List view / Grid view

Articles

Women in STEM with Avideh Nazeri

15 November 2024 | By

Avideh Nazeri, Vice President of Clinical, Medical and Regulatory for Novo Nordisk UK, reflects on her journey through the world of STEM, highlighting the resilience and determination required to overcome biases and challenges along the way. She discusses how perseverance, collaboration and independent thinking have shaped her career, and offers…

Leveraging agonist antibodies to address immunological diseases

7 November 2024 | By

Therapeutic antibodies play a key role in addressing unmet medical needs. Here, Dr Judy Chou, CEO, President and Board Member of AltruBio, Inc, explains how agonist antibodies show potential as a novel therapeutic approach in immunological diseases, helping to mediate interactions between circulating immune cells and influencing the intensity and…

The essential role of recombinant phage display antibody libraries

5 November 2024 | By

The emergence of new antibody-based therapeutics, such as antibody-drug conjugates, alongside a continued drive towards alternatives to animal testing approaches, highlights the need for precise and sensitive tools enabling the identification and characterisation of the best drug candidates for clinical progression. Capable of keeping up with the evolving drug development…

Chemical choreography: orchestrating complex API syntheses

1 November 2024 | By

Small molecules are essential for developing effective medicines, but their structural complexity and material behaviour present difficulties. In this article, Chris Brown, Senior Chemist, Onyx Scientific Ltd, discusses how the right technologies and approaches can enhance drug development and mitigate risk from initial phase to commercial launch.

Advanced Therapies Europe: women in STEM with Clare Blue

31 October 2024 | By

The Women in Advanced Therapies pre-day at Advanced Therapies Europe 2024 provided a great forum to address investment in diversity and elevating female leadership. Following this, we spoke to Clare Blue, Senior CMC Consultant at eXmoor Pharma about embracing diversity, how women can seek mentorship and the importance of community…

Unlocking a new molecular space in rapid drug discovery

23 October 2024 | By ,

So-called undruggable pharmaceutical targets could be tackled with intermediate sized drugs such as macrocycles, combining the advantages of small molecules and biologics. The preparation of very large libraries of chemically synthesised intermediate-sized molecules is now in reach with a new technology developed at ETH Zurich. In this article, Dr Michelle…

Harnessing the CD24/Siglec-10 pathway: immunotherapy innovation

17 October 2024 | By

Renowned immunologist Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the CD24/Siglec-10 pathway. He discusses the technical and regulatory hurdles of antibody development, how these therapies compare to existing immunotherapies, and the potential for personalised cancer treatment through biomarker development.

Women in STEM with Cristina de Min

16 October 2024 | By

Driven by a passion for early-stage scientific discovery, Cristina de Min, MD, Chief Medical Officer at Topas Therapeutics, transitioned from clinical practice to drug development. Her expertise has played a pivotal role in advancing new treatments, with her achievements demonstrating her commitment to improving patient outcomes.

The hidden risks of over-reliance on healthy donor material

10 October 2024 | By

Developing cell therapies solely with healthy donor material can jeopardise clinical outcomes, introducing risks ranging from faulty preclinical data to manufacturing failures. We spoke to Priya Baraniak, CBO at OrganaBio, who advocates for early integration of diseased donor material, improved biobanking infrastructure, and cross-industry collaboration to develop more effective, patient-relevant…